In vitro activity of moxifloxacin compared to other antimicrobials against streptococci isolated from iatrogenic oral bacteremia in Spain

Oral Microbiology and Immunology

Volumn 19, Issue 5, 2004, Pages 331-335

  Tomas I ^a   Alvarez M ^b   Limeres, J ^a   Otero, J L ^a   Saavedra, E ^b   Lopez Melendez C ^b   Diz, P ^a,c  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL XERAL CÍES   (Spain)

^c NONE   (Spain)

Author keywords

Bacteremia; Dental extractions; Moxifloxacin; Streptococci

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; ERYTHROMYCIN; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; DENTISTRY; FEMALE; HUMAN; IATROGENIC DISEASE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUTH FLORA; NONHUMAN; SPAIN; STREPTOCOCCUS; TOOTH EXTRACTION; VENOUS BLOOD;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTEREMIA; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; FOCAL INFECTION, DENTAL; HUMANS; IATROGENIC DISEASE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; QUINOLINES; SPAIN; STATISTICS, NONPARAMETRIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; TOOTH EXTRACTION;

EID: 4544248361     PISSN: 09020055     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-302x.2004.00167.x     Document Type: Article

References (40)

1. Alcaide F, Carratala J, Linares J, Gudiol F, Martin R. In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin- dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients. Antimicrob Agents Chemother 1996: 40: 2117-2120.
2. Alcaide F, Linares J, Pallares R, Carratala J, Benítez MA, Gudiol F, et al. In vitro activies of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother 1995: 39: 2243-2247.
3. Aracil B, Miñambres M, Oteo J, Torres C, Gómez-Garcés JL, Alós JI. High prevalence of erythromycin resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples: a reservoir of mef genes in commensal bacteria. J Antimicrob Chemother 2001: 48: 592-594.
4. Dajani AS, Bisno AL, Chung KJ, Durack DT, Freed M, Gerber MA, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 1990: 264: 2919-2922.
5. Dajani AD, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 1997: 277: 1794-1801.
6. Doem GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 1996: 40: 891-894.
7. Epstein JB, Chong S, Le ND. A survey of antibiotic use in dentistry. J Am Dent Assoc 2000: 131: 1600-1609.
8. Espósito S, Noviello S, Ianniello F, Novelli A. In vitro activity of moxifloxacin compared to other fluoroquinolones against different erythromycin-resistant phenotypes of group A beta-hemolytic Streptococcus. Chemotherapy 2000: 46: 23-27.
9. Facklam R. What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev 2002: 15: 613-630.
10. Gendron R, Grenier D, Maheu-Robert L. The oral cavity as a reservoir of bacterial pathogens for focal infections. Microbes Infect 2000: 2: 897-906.
11. Hall G, Hedstrom SA, Heimdahl A, Nord CE. Prophylactic administration of penicillins for endocarditis does not reduce the incidence of postextraction bacteremia. Clin Infect Dis 1993: 17: 188-194.
12. Hall G, Heimdahl A, Nord CE. Bacteremia after oral surgery and antibiotic prophylaxis for endocarditis. Clin Infect Dis 1999: 29: 1-10.
13. Hall G, Nord CE, Heimdahl A. Elimination of bacteraemia after dental extraction: comparison of erythromycin and clindamycin for prophylaxis of infective endocarditis. J Antimicrob Chemother 1996: 37: 783-795.
14. Heimdahl A, Hall G, Hedberg M, Sandberg H, Söder P, Tunér K, Nord CE. Detection and quantitation by lysis-filtration of bacteremia after different oral surgical procedures. J Clin Microbiol 1990: 28: 2205-2209.
15. Hoeffken G, Meyer HP, Winter J, Verhoef L, CAP. 1 Study Group. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001: 95: 553-564.
16. Ioannidou S, Tassios PT, Kotsovili-Tseleni A, Foustoukou M, Legakis NJ, Vatopoulos A. Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children. Int J Antimicrob Agents 2001: 17: 195-201.
17. Kandemir S, Ergul N. Grievances in cases using antibiotics due to orodental problems and assessment of the need for antibiotics. Int Dent J 2000: 50: 73-77.
18. Levy SB. Multidrug resistance-a sign of the times. N Engl J Med 1998: 338: 1376-1378.
19. Li X, Kolltveit KM, Tronstad L, Olsen I. Systemic diseases caused by oral infection. Clin Microbiol Rev 2000: 13: 547-558.
20. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology, 7th edn. Washington D.C.: American Society for Microbiology, 1999.
21. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; Twelfth Informational (Suppl.): Document M100-S12. Wayne, PA: NCCLS, 2002.
22. Navazesh M, Mulligan R. Systemic dissemination as a result of oral infection in individuals 50 years of age and older. Spec Care Dentist 1995: 15: 11-19.
23. Nishi J, Yoshinaga M, Nomura Y, Dajani AS, Taubert KA, Ferrieri PL. Prevalence of penicillin-resistant viridans streptococci in the oral flora of Japanese children at risk for infective endocarditis. Circulation 1999: 99: 1274-1275.
24. Pallasch TJ. Global antibiotic resistance and its impact on the dental community. J Calif Dent Assoc 2000: 28: 215-233.
25. Parish LC, Witkowski JA, Routh HB. Moxifloxacin (Avelox) for the treatment of bacterial skin infections. Skin Therapy Lett 2001: 6: 1-2.
26. Pérez-Trallero E, Vicente D, Montes M, Marimon JM, Piñeiro L. High proportion of pharyngeal carriers of commensal streptococci resistant to erythromycin in Spanish adults. J Antimicrob Chemother 2001: 48: 225-229.
27. Roberts GJ, Gardner P, Longhurst P, Black AE, Lucas VS. Intensity of bacteraemia associated with conservative dental procedures in children. Br Dent J 2000: 188: 95-98.
28. Roberts GJ, Watts R, Longhurst P, Gardner P. Bacteremia of dental origin and antimicrobial sensitivity following oral surgical procedures in children. Pediatr Dent 1998: 20: 28-36.
29. Rodríguez-Avial I, Rodríguez-Avial C, Culebras E, Benítez A, Picazo JJ. Distribution of mef (A) and erm (B) genes in macrolide-resistant blood isolates of viridans group streptococci. J Antimicrob Chemother 2001: 47: 727-728.
30. Rodríguez-Avial I, Rodríguez-Avial C, Picazo JJ. In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin. Rev Esp Quimioter 2001: 14: 364-368.
31. Romero J, Bouza E, Loza Fernández E, Planes A, Rodríguez A. Procedimientos en Microbiología Clínica, 3: Hemocultivos. Spain: Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, 1993.
32. Ruoff KL. Miscellaneous catalase-negative, Gram-positive cocci: emerging opportunists. J Clin Microbiol 2002: 40: 1129-1133.
33. Ruoff KL, Whiley RA, Beighton D. Streptococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology, 7th edn. Washington D.C.: American Society for Microbiology, 1999: 283-295.
34. Schaberg T, Ballin I, Huchon G, Bassaris H, Hampel B, Reimnitz P, AECB Study Group. A multinational, multicentre, non-blinded, randomized study moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 2001: 29: 314-328.
35. Siegert R, Gehanno P, Nikolaidis P, Bagger-Sjoback D, Ibañez JM, Hampel B, Sommerauer B. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med 2000: 94:337-344.
36. Simmons NA. British Society for Antimicrobial Chemotherapy Working Party report. Recommendations for endocarditis prophylaxis. J Antimicrob Chemother 1993: 31: 437-438.
37. Sobottka I, Cachovan G, Stürenburg E, Ahlers MO, Laufs R, Platzer U, Mack D. In vitro activity of moxifloxacin against bacteria isolated from odontogenic abscesses. Antimicrob Agents Chemother 2002: 46: 4019-4021.
38. Teng LJ, Hsueh PR, Chen YC, Ho SW, Luh KT. Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis. J Antimicrob Chemother 1998: 41: 621-627.
39. Wu JJ, Lin KY, Hsueh PR, Liu JW, Pan HI, Sheu SM. High incidence of erythromycin resistant Streptococci in Taiwan. Antimicrob Agents Chemother 1997: 41: 844-846.
40. Yagupsky P, Katz O, Peled N, Dagan R. In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media. Chemotherapy 2001: 47: 354-358.